These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

991 related articles for article (PubMed ID: 27718153)

  • 1. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis.
    Luo Y; Qin Y; Lang J
    Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcome and Prognostic Factors of Intensity-Modulated Radiotherapy for T4 Stage Nasopharyngeal Carcinoma.
    Luo Y; Gao Y; Yang G; Lang J
    Biomed Res Int; 2016; 2016():4398498. PubMed ID: 27195286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
    Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J
    Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replanning during intensity modulated radiation therapy improved quality of life in patients with nasopharyngeal carcinoma.
    Yang H; Hu W; Wang W; Chen P; Ding W; Luo W
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e47-54. PubMed ID: 23122981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy.
    He YX; Wang Y; Cao PF; Shen L; Zhao YJ; Zhang ZJ; Chen DM; Yang TB; Huang XQ; Qin Z; Dai YY; Shen LF
    Chin J Cancer; 2016 Nov; 35(1):96. PubMed ID: 27852284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy in locally advanced nasopharyngeal carcinoma: Comparative study at SKIMS Tertiary Care Institute.
    Fatima K; Andleeb A; Sofi MA; Rasool MT; Fir A; Nasreen S; Dar NA
    J Cancer Res Ther; 2022; 18(1):133-139. PubMed ID: 35381774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
    Zhang LN; Gao YH; Lan XW; Tang J; Su Z; Ma J; Deng W; OuYang PY; Xie FY
    Oncotarget; 2015 Dec; 6(41):44019-29. PubMed ID: 26528755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of long-term survival outcomes and failure patterns of patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: a retrospective analysis.
    Zhao W; Lei H; Zhu X; Li L; Qu S; Liang X
    Oncotarget; 2016 Dec; 7(52):86914-86925. PubMed ID: 27894100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up.
    Zhang MX; Li J; Shen GP; Zou X; Xu JJ; Jiang R; You R; Hua YJ; Sun Y; Ma J; Hong MH; Chen MY
    Eur J Cancer; 2015 Nov; 51(17):2587-95. PubMed ID: 26318726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy alone in nasopharyngeal carcinoma.
    OuYang PY; Shi D; Sun R; Zhu YJ; Xiao Y; Zhang LN; Zhang XH; Chen ZY; Lan XW; Tang J; Gao YH; Ma J; Deng W; Xie FY
    Oncotarget; 2016 May; 7(22):33408-17. PubMed ID: 27058901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
    Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
    Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET/CT-guided dose-painting versus CT-based intensity modulated radiation therapy in locoregional advanced nasopharyngeal carcinoma.
    Liu F; Xi XP; Wang H; Han YQ; Xiao F; Hu Y; He Q; Zhang L; Xiao Q; Liu L; Luo L; Li Y; Mo Y; Ma HZ
    Radiat Oncol; 2017 Jan; 12(1):15. PubMed ID: 28587681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
    Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
    Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of wait time in nasopharyngeal carcinoma treated with intensity modulated radiotherapy: a propensity matched analysis.
    Chen YP; Mao YP; Zhang WN; Chen L; Tang LL; Li WF; Liu X; Zhou GQ; Guo R; Sun Y; Kang TB; Zeng MS; Ma J
    Oncotarget; 2016 Mar; 7(12):14973-82. PubMed ID: 26942870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
    Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
    Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.
    Su SF; Han F; Zhao C; Huang Y; Chen CY; Xiao WW; Li JX; Lu TX
    Chin J Cancer; 2011 Aug; 30(8):565-73. PubMed ID: 21801605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure patterns of locoregional recurrence after reducing target volumes in patients with nasopharyngeal carcinoma receiving adaptive replanning during intensity-modulated radiotherapy: a single-center experience in China.
    Zhou X; Zhu J; Zhou C; Wang W; Ding W; Chen M; Chen K; Li S; Chen X; Yang H
    Radiat Oncol; 2023 Nov; 18(1):190. PubMed ID: 37974274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II nasopharyngeal carcinoma after intensity-modulated radiotherapy: A propensity score-matched cohort study.
    Wang F; Zhou L; Zhang LJ; Xie CB; Liao ZW; Lin XD; Wen YF
    Radiother Oncol; 2024 Feb; 191():110081. PubMed ID: 38185256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.